WHO to commence trialing malaria, other drugs for COVID-19 treatment
The World Health Organisation announced on Wednesday that it would soon begin a worldwide clinical trial of three new candidate drugs for the treatment of COVID-19.
The global public health agency said the scheme is being undertaken in the latest phase of global solidarity clinical trials to find effective treatments against COVID-19.
Under the Solidarity PLUS programme, the therapies – artesunate, imatinib and infliximab – will be tested on hospitalised COVID-19 patients in 52 countries.
There have been more than 203 million cases of the disease recorded globally as of Wednesday, according to WHO.
The world hit the 200 million mark last week, just six months after cases passed 100 million.
Speaking during a press conference in Geneva, WHO’s Director-General, Dr Tedros Ghebreyesus, underscored the critical need to find more effective and accessible COVID-19 therapeutics.
“We already have many tools to prevent, test for and treat COVID-19, including oxygen, dexamethasone and IL-6 blockers.
“But we need more, for patients at all ends of the clinical spectrum, from mild to severe disease.
And we need health workers that are trained to use them in a safe environment,” he said.
The three drugs were selected by an independent panel for their potential in reducing the risk of death in people hospitalised for COVID-19.
They are already being used to treat other conditions.
Artesunate is a medicine for severe malaria, imatinib is used for certain cancers, including leukemia, while infliximab is used to treat Crohn’s Disease, rheumatoid arthritis and other diseases of the immune system.
Manufacturers Ipca, Novartis and Johnson & Johnson, donated the drugs for the trial.
Solidarity PLUS is the largest global collaboration among WHO’s 194 Member States, with thousands of researchers in over 600 hospitals participating.
Finland is among the 52 countries taking part, 16 more than the initial Solidarity Trial, and contributes to the COVAX vaccine solidarity initiative. Two university hospitals in Finland have been the first worldwide to begin the second phase.
Hanna Sarkkinen, the country’s Minister of Social Affairs and Health, said clinical trials had a great potential to save lives.
“Even though there are approximately 3,000 clinical studies on COVID-19, most of them are too small to yield significant information. We need clinical trials that are large enough to bring better treatments for COVID-19 patients,” she said.
Four drugs were evaluated under the initial Solidarity Trial in 2020, which showed that remdesivir, hydroxychloroquine, lopinavir and interferon had little or no effect on hospitalised patients with COVID-19.
(NAN)
We have recently deactivated our website's comment provider in favour of other channels of distribution and commentary. We encourage you to join the conversation on our stories via our Facebook, Twitter and other social media pages.
More from Peoples Gazette
Politics
Katsina youths pledge to deliver over 2 million votes to Atiku
“Katsina State is Atiku’s political base because it is his second home.”
Sport
Iheanacho, Ndidi secure Premier League promotion with Leicester City
Leicester City have now secured one of the two automatic promotion tickets to the Premier League.
Economy
BDC operators warn against naira speculation, hoarding
He added that ABCON will upgrade technology in its quest to help in the fight against the sabotage of CBN’s reforms.
Economy
Tinubu taps Jim Ovia to lead Nigerian education loan fund
The prominent Nigerian banker was appointed on Friday.
Heading 4
Liverpool agree compensation with Feyenoord to appoint Arne Slot as new manager
Liverpool had initially shown interest in former player and Bayer Leverkusen manager Xabi Alonso.
Agriculture
Taraba govt. set to distribute first set of tractors to farmers
“We have so far received 20 Cabrio and 250 mini high powered tractors that would be distributed to our farmers on May 28.”
NationWide
Jonathan mourns Ayogu Eze
The former president commiserated with the Eze family, his political and professional colleagues in the media.